Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $10.00 price objective on the biotechnology company's stock. HC Wainwright's price target would indicate a potential upside of 362.96% from the stock's previous close.
Separately, BTIG Research decreased their price target on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Monday, April 7th.
Check Out Our Latest Stock Analysis on Aldeyra Therapeutics
Aldeyra Therapeutics Price Performance
Shares of NASDAQ ALDX opened at $2.16 on Monday. The firm has a market capitalization of $129.38 million, a P/E ratio of -2.23 and a beta of 0.92. The firm's 50-day moving average price is $3.56 and its 200-day moving average price is $4.73. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics has a 1-year low of $1.14 and a 1-year high of $7.20.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.08. Equities research analysts anticipate that Aldeyra Therapeutics will post -0.92 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of Aldeyra Therapeutics stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the transaction, the insider now directly owns 5,875,851 shares of the company's stock, valued at $8,343,708.42. The trade was a 36.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 9.60% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in ALDX. Geode Capital Management LLC boosted its holdings in Aldeyra Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company's stock worth $5,588,000 after purchasing an additional 4,927 shares during the last quarter. Kingdon Capital Management L.L.C. bought a new position in shares of Aldeyra Therapeutics in the first quarter valued at approximately $4,479,000. Dimensional Fund Advisors LP lifted its holdings in Aldeyra Therapeutics by 21.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 735,763 shares of the biotechnology company's stock worth $3,672,000 after acquiring an additional 131,722 shares during the period. Raymond James Financial Inc. bought a new stake in Aldeyra Therapeutics during the fourth quarter worth $3,628,000. Finally, ADAR1 Capital Management LLC boosted its position in Aldeyra Therapeutics by 114.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 647,960 shares of the biotechnology company's stock worth $3,233,000 after purchasing an additional 345,748 shares during the last quarter. 59.71% of the stock is owned by institutional investors.
About Aldeyra Therapeutics
(
Get Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aldeyra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aldeyra Therapeutics wasn't on the list.
While Aldeyra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
